Marketing: Page 3

  • A person wearing a lab coat looks on at a laptop at a table. There is notebook beside the laptop, and two people in lab coats out of focus in the background..
    Image attribution tooltip

    Alarmy.com/Yuri Arcurs

    Image attribution tooltip
    Sponsored by First Republic Bank

    Building the dream team: How life science startups can attract top talent

    Learn how to attract and retain top talent, in an ultra-competitive labor market.

    By Nishta Rao, Managing Director, Life Science, First Republic Bank • Oct. 17, 2022
  • GoodRx's provider mode platform
    Image attribution tooltip
    Courtesy of GoodRx
    Image attribution tooltip

    GoodRx launches new push to draw in doctors

    Targeting providers directly is a pivot for GoodRx, but the company sees an opportunity to capture more pharmaceutical advertising revenue, said executive Preeti Parikh.

    By Hailey Mensik • Oct. 13, 2022
  • Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    Omicron boosters from Pfizer, Moderna cleared by FDA for younger children

    Pfizer's reformulated vaccine is now authorized for use in children at least 5 years of age, while Moderna's will be available for kids as young as 6.

    By • Oct. 12, 2022
  • A building with logo of drugmaker Eli Lilly.
    Image attribution tooltip
    Eli Lilly & Co.
    Image attribution tooltip
    Obesity drugs

    Lilly looks to speed FDA review of new diabetes drug in obesity

    A new fast track designation allows Lilly to begin the process of seeking approval of tirzepatide for obesity, though the drug will need to succeed in a second trial to get to market.  

    By • Oct. 6, 2022
  • Biogen
    Image attribution tooltip
    Permission granted by Biogen
    Image attribution tooltip

    Biogen to pay $900M to settle lawsuit over MS drug outreach

    A former Biogen employee sued in 2012, alleging the company paid physician fees to encourage prescribing of its drugs. Biogen did not admit wrongdoing as part of the settlement.

    By • Sept. 27, 2022
  • Young female physician working in a lab
    Image attribution tooltip

    iStock.com/yalax

    Image attribution tooltip
    Sponsored by flipMD from GoodRx

    Optimizing pharmaceutical innovation

    Elevate pharma product development and marketing through collaboration with physician experts

    Sept. 19, 2022
  • A photo of Sanofi headquarters in Paris, France.
    Image attribution tooltip
    Courtesy of Sanofi
    Image attribution tooltip

    Sanofi, AstraZeneca secure EMA support for RSV drug in babies

    If authorized by the European Commission, the companies’ antibody medicine would become the first cleared for broad use in newborns and infants. 

    By • Sept. 16, 2022
  • Exterior sign of Bristol-Myers Squibb
    Image attribution tooltip
    Permission granted by Bristol-Myers Squibb
    Image attribution tooltip

    Bristol Myers gets FDA approval for new type of psoriasis drug

    Sotyktu has been on the pharma’s top pipeline candidates and its clearance continues a string of positive regulatory news for the company.

    By • Updated Sept. 12, 2022
  • The sign identifying the FDA headquarters in front of its building in White Oak, Maryland.
    Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    FDA names new head to vaccine review office

    David Kaslow, the lead scientist at a global public health nonprofit, will succeed Marion Gruber, who retired last fall amid her dissent on the timing of COVID-19 vaccine boosters.

    By • Sept. 9, 2022
  • Image attribution tooltip
    Getty Images
    Image attribution tooltip

    FDA holds back Alvotech’s Humira biosimilar over manufacturing issues

    The company received a complete response letter, but still expects to win approval of the copycat drug in time to launch it in the U.S. next year.

    By • Sept. 6, 2022
  • a nurse gives a vaccination to a woman sitting in a chair
    Image attribution tooltip
    Joe Raedle/Getty Images via Getty Images
    Image attribution tooltip

    Funds for free COVID-19 vaccines could run out as early as January, HHS says

    The commercial market for COVID-19 vaccinations could be similar to that for seasonal flu shots and other vaccines, an official with the department said.

    By Sydney Halleman • Aug. 31, 2022
  • The FDA logo on a glass pane at the agency's campus in Silver Spring, Maryland.
    Image attribution tooltip
    Jacob Bell / BioPharma Dive
    Image attribution tooltip

    Incyte secures second approval for targeted cancer drug

    Sold as Pemazyre, the drug, which blocks well-known cancer proteins known as FGFRs, is now also cleared for use in certain patients with very rare and aggressive blood cancers.

    By • Aug. 29, 2022
  • Magic Mushrooms in laboratory. Psilocybin science and research. Person examining fungi.
    Image attribution tooltip
    24K-Production via Getty Images
    Image attribution tooltip
    Sponsored by Worldwide Clinical Trials

    Psychedelic clinical trials: What sponsors should know when designing new protocols

    With regulators and lawmakers seemingly on board, sponsors have more opportunities than ever to pursue clinical research in this high-velocity area.

    Aug. 29, 2022
  • Glass vials of Moderna COVID-19 vaccine.
    Image attribution tooltip
    Gabriel Kuchta via Getty Images
    Image attribution tooltip

    Moderna sues Pfizer, BioNTech over COVID-19 vaccine technology

    The biotech claims its rivals’ vaccine Comirnaty, one of the world’s top-selling pharmaceutical products, infringes on two patents covering its messenger RNA technology.

    By • Aug. 26, 2022
  • Image attribution tooltip
    Jacob Bell
    Image attribution tooltip

    Novartis begins plans to spin off generic drug business

    After reviewing multiple options including a possible sale, the Swiss drugmaker said spinning off Sandoz would give the division “greater freedom to operate” and capitalize on newly growing sales.

    By • Aug. 25, 2022
  • A sign at Gilead Sciences
    Image attribution tooltip
    Permission granted by Gilead Sciences
    Image attribution tooltip

    Gilead breaks through with first approval for new HIV drug

    European authorities cleared Gilead’s long-acting shot for patients whose HIV infection is resistant to other drugs. An FDA decision is expected by December.

    By • Aug. 22, 2022
  • A child plays EndeavorRx on a tablet. The digital therapeutic intended to improve attention in kids with ADHD.
    Image attribution tooltip
    Permission granted by Akili Interactive
    Image attribution tooltip

    Digital medicine company Akili gets cold market reception after blank-check merger

    After spiking on news of the merger’s close, shares in the ADHD treatment developer fell sharply in trading.

    By Elise Reuter • Updated Aug. 23, 2022
  • Transmission electron micrograph of a SARS-CoV-2 virus particle, isolated from a patient.
    Image attribution tooltip
    National Institute of Allergy and Infectious Diseases. (2020). "Novel Coronavirus SARS-CoV-2" [Image]. Retrieved from Flickr.
    Image attribution tooltip

    US plans shift to private market sales of COVID-19 vaccines, drugs

    The federal government will begin the transition as early as this fall, clearing the way for drugmakers to control sales and distribution of their medicines.

    By • Aug. 17, 2022
  • Glass vials of Moderna COVID-19 vaccine.
    Image attribution tooltip
    Gabriel Kuchta via Getty Images
    Image attribution tooltip

    UK approves Moderna’s two-pronged COVID-19 booster

    Britain’s drug regulator is the first public health authority to clear a vaccine designed to fight omicron as well as the original strain of the virus. 

    By • Aug. 15, 2022
  • Image attribution tooltip
    Jeenah Moon via Getty Images
    Image attribution tooltip

    Pfizer’s new pneumococcal vaccine meets study goal in children

    Pfizer, which competes with Merck in this market, plans to ask the FDA for an expanded approval of its 20-valent shot later this year.

    By • Aug. 12, 2022
  • In this photo illustration, packages and pills of Zantac sit on a table on September 19, 2019 in New York City.
    Image attribution tooltip
    Drew Angerer via Getty Images
    Image attribution tooltip

    GSK, Pfizer, Sanofi shares drop amid Zantac litigation concerns

    The companies could face liability related to their sales of the heartburn drug, which was withdrawn from the market in the U.S. and other countries after impurities related to a likely carcinogen were detected.

    By • Updated Aug. 11, 2022
  • A sign for the Food And Drug Administration is seen outside of the headquarters on July 20, 2020, in White Oak, Maryland.
    Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    Coherus wins FDA approval for second Lucentis biosimilar, its third drug

    The biotech company secured a valuable interchangeable designation for the copycat medicine, which it plans to launch later this year.

    By Kristin Jensen • Aug. 3, 2022
  • Roche Pharmaceutical Group's office building in Shanghai, China
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    With new data, Roche takes step toward more convenient cancer immunotherapy

    The pharma claimed Phase 3 study success for a subcutaneous version of its drug Tecentriq, a strategy it and rivals Merck and Bristol Myers could use to extend the market life of their lucrative drugs.

    By • Aug. 2, 2022
  • A general view of AstraZeneca is seen during Prime Minister Scott Morrison's visit on August 19, 2020 in Sydney, Australia.
    Image attribution tooltip
    Lisa Maree Williams via Getty Images
    Image attribution tooltip

    AbbVie cancer drug sales fall as AstraZeneca competitor gains ground

    Imbruvica, long one of AbbVie’s top-selling medicines, has ceded market share in treating chronic lymphocytic leukemia to AstraZeneca’s Calquence.

    By • July 29, 2022
  • A general view of the Pfizer Headquarters sign on November 10, 2020 in Tadworth, England.
    Image attribution tooltip
    Dan Kitwood via Getty Images
    Image attribution tooltip

    Pfizer sales of COVID-19 vaccine, pill beat forecasts as company prepares for future waves

    The company plans to ready a booster shot by the fall that targets the BA.4 and BA.5 strains that are currently most prevalent in the U.S. and other countries.

    By • Updated July 28, 2022